Relay Therapeutics, Inc.
A clinical-stage biotechnology company in Cambridge, Massachusetts, that designs small-molecule medicines by studying how proteins move and change shape, using its Dynamo platform to create "movies" of protein motion rather than static snapshots. Founded in 2015 as Allostery, Inc., it was renamed Relay Therapeutics to reflect that focus on protein motion, and its lead drug candidate targets a common mutation in breast cancer.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Commodore Capital LP | 13G/APassive | 5.5% | 12.00M | Aug 14, 2026 |
| Commodore Capital Master LP | 13G/APassive | 5.5% | 12.00M | Aug 14, 2026 |
| Robert Egen Atkinson | 13G/APassive | 5.5% | 12.00M | Aug 14, 2026 |
| Michael Kramarz | 13G/APassive | 5.5% | 12.00M | Aug 14, 2026 |
| Perceptive Advisors LLC | 13G/APassive | 6.4% | 14.11M | Aug 10, 2026 |
| Joseph Edelman | 13G/APassive | 6.4% | 14.11M | Aug 10, 2026 |
| Perceptive Life Sciences Master Fund, Ltd. | 13G/APassive | 6.4% | 14.11M | Aug 10, 2026 |
| FMR LLC | 13G/APassive | 10% | 21.27M | Aug 7, 2026 |
| Abigail P. Johnson | 13G/APassive | 10% | 21.27M | Aug 7, 2026 |
| Point72 Asset Management, L.P. | 13G/APassive | 0% | 0 | May 15, 2026 |